


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:50:38Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12405770" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12405770</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>jkaoms</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="case-report" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Korean Assoc Oral Maxillofac Surg</journal-id><journal-id journal-id-type="iso-abbrev">J Korean Assoc Oral Maxillofac Surg</journal-id><journal-id journal-id-type="pmc-domain-id">2169</journal-id><journal-id journal-id-type="pmc-domain">jkaoms</journal-id><journal-title-group><journal-title>Journal of the Korean Association of Oral and Maxillofacial Surgeons</journal-title></journal-title-group><issn pub-type="ppub">2234-7550</issn><issn pub-type="epub">2234-5930</issn><publisher><publisher-name>Korean Association of Oral and Maxillofacial Surgeons</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12405770</article-id><article-id pub-id-type="pmcid-ver">PMC12405770.1</article-id><article-id pub-id-type="pmcaid">12405770</article-id><article-id pub-id-type="pmcaiid">12405770</article-id><article-id pub-id-type="pmid">40878420</article-id><article-id pub-id-type="doi">10.5125/jkaoms.2025.51.4.254</article-id><article-id pub-id-type="publisher-id">jkaoms-51-4-254</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Isolated bilateral temporalis hypertrophy: a rare case report and technical insight into botulinum toxin type A injection</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0006-1553-9609</contrib-id><name name-style="western"><surname>Akta&#351;</surname><given-names initials="S">Suat</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0628-2419</contrib-id><name name-style="western"><surname>Uranbey</surname><given-names initials="&#xD6;">&#214;mer</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9893-0649</contrib-id><name name-style="western"><surname>G&#252;rsoytrak</surname><given-names initials="B">Burcu</given-names></name><xref rid="aff1" ref-type="aff"/><xref rid="cor1" ref-type="corresp"/></contrib></contrib-group><aff id="aff1">Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Ayd&#305;n Adnan Menderes University, Ayd&#305;n, <country>T&#252;rkiye</country></aff><author-notes><corresp id="cor1">Burcu G&#252;rsoytrak, Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Ayd&#305;n Adnan Menderes University, Hasan Efendi St. No:40, Efeler, Ayd&#305;n 09100, T&#252;rkiye, TEL: +90-543-741-72-35, E-mail: <email xlink:href="dt_burcupoyraz@hotmail.com">dt_burcupoyraz@hotmail.com</email>, ORCID: <ext-link xlink:href="https://orcid.org/0000-0002-9893-0649" ext-link-type="uri">https://orcid.org/0000-0002-9893-0649</ext-link></corresp></author-notes><pub-date pub-type="ppub"><day>31</day><month>8</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>31</day><month>8</month><year>2025</year></pub-date><volume>51</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">496108</issue-id><fpage>254</fpage><lpage>260</lpage><history><date date-type="received"><day>24</day><month>7</month><year>2025</year></date><date date-type="rev-recd"><day>19</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>19</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>31</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 The Korean Association of Oral and Maxillofacial Surgeons. All rights reserved.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0</ext-link>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="jkaoms-51-4-254.pdf"/><abstract><p>Isolated bilateral temporalis muscle hypertrophy (IBTMH) is a rare clinical condition characterized by symmetrical enlargement of the temporalis muscles without masseter involvement. This case report presents a 47-year-old male with progressive bilateral temporal swelling and discomfort during mastication, significantly affecting his quality of life. Clinical examination and magnetic resonance imaging (MRI) confirmed homogenous enlargement of the temporalis muscles with no underlying pathology. The patient was treated with botulinum toxin type A (BTxA) injections in two sessions, following anatomical landmarks and established guidelines to ensure safety and efficacy. Post-treatment follow-ups revealed significant improvement in symptoms and normalization of temporal contours, with MRI confirming muscle volume reduction. This case contributes to the limited literature on IBTMH and supports BTxA as a safe, non-invasive, and effective treatment modality. It also underscores the need for standardized injection techniques to minimize complications in the anatomically complex temporal region. Further case reports and research are essential to improve clinical understanding and guide best practices for diagnosis and management of this rare entity.</p></abstract><kwd-group><kwd>Hypertrophy</kwd><kwd>Botulinum toxins</kwd><kwd>Muscular diseases</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>I. Introduction</title><p>The human masticatory system is a dynamic and adaptive system that responds to a complex interaction of genetic, functional and environmental factors. Among these adaptations, hypertrophy of the masticatory muscles was first documented by Legg<sup><xref rid="ref1" ref-type="bibr">1</xref></sup> in 1880. The muscles under consideration comprise four primary muscle groups: the temporalis, lateral pterygoid, medial pterygoid, and masseter<sup><xref rid="ref2" ref-type="bibr">2</xref></sup>. The temporalis muscle originates in the temporal fossa of the temporal bone and adheres to the bone by extending to the coronoid process of the mandible. This muscle is composed of three distinct parts: the anterior fibers are oriented vertically, the middle fibers run obliquely, and the posterior fibers are aligned horizontally. It is the largest muscle involved in mastication. The fibers of the anterior and middle sections function to elevate the mandible, facilitating occlusion of the teeth, whereas the fibers of the posterior section contribute to mandibular retraction<sup><xref rid="ref2" ref-type="bibr">2</xref></sup>.</p><p>Isolated bilateral temporal muscle hypertrophy (IBTMH) is a rare clinical entity. To date, the literature contains only a small number of documented cases<sup><xref rid="ref3" ref-type="bibr">3</xref><xref rid="ref4" ref-type="bibr"/><xref rid="ref5" ref-type="bibr"/><xref rid="ref6" ref-type="bibr"/>-<xref rid="ref7" ref-type="bibr">7</xref></sup>. The scientific literature documents cases of bilateral temporal muscle hypertrophy, which are predominantly associated with the masseter muscle<sup><xref rid="ref3" ref-type="bibr">3</xref>,<xref rid="ref8" ref-type="bibr">8</xref></sup>. Although congenital cases have been documented, acquired hypertrophy is significantly more prevalent and is frequently associated with hyperactivity in the stomatognathic system<sup>3</sup>.</p><p>Computed tomography, magnetic resonance imaging (MRI), ultrasonography, muscle biopsy are useful for diagnosis<sup><xref rid="ref4" ref-type="bibr">4</xref></sup>. Surgical reduction is a radical treatment option and is outdated<sup><xref rid="ref9" ref-type="bibr">9</xref></sup>. The injection of botulinum toxin type A (BTxA) is the preferred non-invasive method of treatment<sup><xref rid="ref4" ref-type="bibr">4</xref></sup>. Although it is considered a safe treatment method, the lack of a methodological standard for injection administration and the complex anatomical structure of the temporal region bring with it various morbidity risks<sup><xref rid="ref10" ref-type="bibr">10</xref></sup>. Therefore, it is of great importance for the clinician to have a complete understanding of topographic anatomy.</p><p>In this case report, BTxA injection was applied as a treatment option in the management of symptoms in order to contribute to the rare cases of IBTMH in the literature. The report was prepared in accordance with the CAse REport (CARE) guidelines and relevant ethical principles to ensure comprehensive, transparent, and standardized documentation.</p></sec><sec sec-type="other"><title>II. Case Report</title><p>A 47-year-old male patient was admitted to our clinic with complaints of marked swelling in the right and left temporal region and a sensation of contraction during the act of eating. The initial observation of the swelling was made by his relatives during his meals approximately four to five years prior. The patient&#8217;s complaints increased especially in parallel with masticatory function. Even in the absence of food intake, his symptoms tend to worsen as the day goes on. Muscle contractions in the temporal region during mastication hinder the patient&#8217;s ability to eat. The active complaints started 4-5 months ago. The patient has no history of bruxism, temporomandibular joint disease, surgical intervention, or trauma involving the affected area.</p><p>The patient has been under psychiatric treatment for 10-12 years and is currently taking lithium carbonate, escitalopram, olanzapine, and alprazolam. Valsartan has been prescribed for the management of hypertension. Additionally, the patient has undergone angioplasty and reports experiencing nocturnal insomnia. The patient&#8217;s current polypharmacy, were taken into account during the diagnostic process and treatment planning.</p><p>A thorough extraoral examination revealed a palpable, large, soft swelling in the right and left temporal region. No other significant clinical findings were observed. A thorough evaluation of the panoramic radiographic image revealed no indications of abnormality.(<xref rid="F1" ref-type="fig">Fig. 1</xref>) The results of MRI imaging revealed homogeneous muscle enlargement in the right and left temporalis muscle region, with no underlying pathology or intracranial abnormality identified.(<xref rid="F2" ref-type="fig">Fig. 2</xref>) The diagnosis of IBTMH was made subsequent to a combination of clinical and radiological examinations. No clinical or radiological signs suggestive of drug-induced myopathy or dystonia were observed, and none of the medications used by the patient are known to be associated with localized hypertrophy of the temporalis muscle. Prior to the administration of BTxA, interdisciplinary consultation confirmed the absence of contraindications or potential drug interactions.</p><p>The treatment protocol encompassed two sessions of percutaneous injection of BTxA (BTXA; Allergan). During the application, the areas at least 45 mm superior to the zygomatic arch were applied to avoid injection into the tendon of the temporal muscle.(<xref rid="F3" ref-type="fig">Fig. 3</xref>) Care was taken to ensure bone contact to avoid injection into the fascial layer. For botulinum toxin injection, the 9-square method described by Lee et al.<sup><xref rid="ref10" ref-type="bibr">10</xref></sup> was employed, using anatomical landmarks and reference lines between the lateral canthus and tragus to divide the temporalis muscle into nine compartments for precise localization.</p><p>The area of application is intended to be the anterior belly of the temporal muscle above the imaginary line drawn transversely from the upper border of the orbit, anterior to the imaginary vertical line drawn from the tragus. Injection was performed with a safety margin of 2 cm from the orbital rim. In a single session, 30 units of BTxA (BTXA; Allergan) were administered to the bilateral temporalis muscles, with 10 units injected into each of the anterior-middle (Am), mid-upper (Mu) and posterior-middle (Pm) compartments. The procedure was repeated four weeks later using the same dose and technique. The patient was followed postoperatively at 4-week intervals. Symptoms decreased following the BTxA application, and temporal muscle contours were observed within normal limits 8 weeks after the injection.(<xref rid="F4" ref-type="fig">Fig. 4</xref>) The reduction in the size of the temporal muscle on the MRI scan 3 months after the procedure is remarkable.(<xref rid="F5" ref-type="fig">Fig. 5</xref>) Throughout the treatment and follow-up period of 1 year, the patient&#8217;s psychiatric status remained stable, and no adverse effects related to botulinum toxin were noted. A step-by-step flowchart outlining the BTxA injection protocol is presented in <xref rid="F6" ref-type="fig">Fig. 6</xref>.</p></sec><sec sec-type="discussion"><title>III. Discussion</title><p>Hypertrophy of the temporalis muscle is rarely reported in the literature. The majority of these cases are associated with masseter hypertrophy, and isolated cases involving only the temporalis muscle are much rarer<sup><xref rid="ref3" ref-type="bibr">3</xref></sup>. Moreover, even isolated cases of unilateral temporal muscle hypertrophy have been reported very rarely, while only 6 cases of IBTMH have been reported to our knowledge<sup><xref rid="ref3" ref-type="bibr">3</xref><xref rid="ref4" ref-type="bibr"/><xref rid="ref5" ref-type="bibr"/><xref rid="ref6" ref-type="bibr"/>-<xref rid="ref7" ref-type="bibr">7</xref></sup>. The first case report was presented by Van Lierde<sup><xref rid="ref11" ref-type="bibr">11</xref></sup> in 1985 and since it was a paediatric case, correct diagnosis and differential diagnoses were emphasised without invasive treatment. The other 5 cases are after 2000<sup>3,4,6,7,9</sup>. The most recent case belongs to Gomez and Cuellar<sup><xref rid="ref6" ref-type="bibr">6</xref></sup> was shared in 2020. In the cases of Gomez and Cuellar<sup><xref rid="ref6" ref-type="bibr">6</xref></sup>, and Morselli<sup><xref rid="ref9" ref-type="bibr">9</xref></sup>, it is not clear whether the bilateral hypertrophy is isolated to the temporal muscle. A comparative summary of these five previously reported cases is presented in <xref rid="T1" ref-type="table">Table 1</xref> to help contextualise the current case within the existing literature.</p><p>In this context, the case of bilateral isolated temporal muscle hypertrophy presented in our study is among few similar cases in the literature and contributes to the understanding of this rare clinical picture. Given the anatomical complexity of the region in which the temporal muscle is located, the administration of injections in this area carries a certain degree of risk due to potential complications. Post-injection complications such as superficial temporal artery pseudoaneurysm, temporal hollowing, eyelid ptosis due to periorbital muscle involvement and hourglass deformity due to temporal muscle atrophy have been reported<sup><xref rid="ref12" ref-type="bibr">12</xref><xref rid="ref13" ref-type="bibr"/><xref rid="ref14" ref-type="bibr"/>-<xref rid="ref15" ref-type="bibr">15</xref></sup>. Appropriate patient selection, precise injection techniques, and a thorough understanding of the anatomy are essential to minimize these risks and effectively manage complications.</p><p>To enhance the efficacy and safety of BTxA injections into the temporalis muscle, there remains a need for standardized injection techniques that consider anatomical variations<sup><xref rid="ref12" ref-type="bibr">12</xref></sup>. In order to ensure standardization, Choi et al.<sup><xref rid="ref16" ref-type="bibr">16</xref></sup> stated that the injection should be performed at least 45 mm above the zygomatic arch. This method aims to prevent the injection from reaching the tendonous part of the muscle, limiting the effect of the toxin only to the muscle belly area where the motor nerve branches are concentrated<sup><xref rid="ref16" ref-type="bibr">16</xref></sup>. According to Choi et al.<sup><xref rid="ref16" ref-type="bibr">16</xref></sup>, during injection, the needle should reach the bone surface after passing through the superficial and deep temporal fascia layers and should be administered retrogradely. This technique increases the effectiveness of botulinum toxin by reducing its spread on the facial plan. In our case, based on this method, an imaginary vertical reference line passing over the tragus was used and injection sites were planned according to this line. Since the posterior temporal muscle region is usually located under the scalp, the muscle belly is difficult to distinguish here; in addition, injections in this region behind the orbital rim can lead to undesirable aesthetic results such as temporal hollowing<sup><xref rid="ref12" ref-type="bibr">12</xref></sup>. For this purpose, the injections were mainly directed to the anterior part of the muscle. According to Yi et al.<sup><xref rid="ref12" ref-type="bibr">12</xref></sup>, injections should be planned according to the anatomical thickness of the muscle and 5 unit of botulinum toxin should be administered to each point, totaling four to five separate points. Since the inferior part of the muscle is thicker, it is recommended to give three injections in the inferior muscle belly and two injections in the superior part in five-point injection plans<sup><xref rid="ref12" ref-type="bibr">12</xref></sup>. Given the average spread diameter of the toxin, injections should be spaced appropriately (2-4 cm) and the total dose should be limited to 20-25 Unit<sup><xref rid="ref12" ref-type="bibr">12</xref></sup>. The active belly region of the temporal muscle is located above an imaginary transversal reference line passing over the superior orbital rim<sup><xref rid="ref12" ref-type="bibr">12</xref></sup>. In our case, we were able to palpate this active part of the hypertrophic muscle bundle by instructing the patient to clench his teeth during the injection.</p><p>In the literature, techniques based on also different anatomical classifications have been described for injection applications to the temporalis muscle. One of them is based on dividing the temporalis muscle into nine regions in an imaginary rectangle and evaluating three of these regions as safe for injection<sup><xref rid="ref10" ref-type="bibr">10</xref></sup>. In this technique proposed by Lee et al.<sup><xref rid="ref10" ref-type="bibr">10</xref></sup>, the imaginary line between the lateral canthus and the tragus point is considered as the reference line. The line perpendicular to this reference line from the most anterior point of the muscle forms the anterior boundary line of the rectangle; the line from the most posterior point forms the posterior boundary line. Likewise, the line perpendicular to these two boundary lines at the top of the muscle defines the upper boundary. This rectangular structure was divided into a total of nine regions, named in three horizontal (upper: u, middle: m, lower : l) and three vertical (anterior: A, superior: S, posterior: P) planes. According to this classification, the regions reported to be safe and effective for injection application are defined as Am, Mu and Pm. Applications that target these anatomical regions are important in terms of both efficacy and reducing the risk of complications<sup><xref rid="ref10" ref-type="bibr">10</xref></sup>.</p><p>In the literature, bilateral temporal muscle hypertrophy is usually reported in association with masseter hypertrophy<sup><xref rid="ref3" ref-type="bibr">3</xref></sup>. At this point, unilateral temporal muscle hypertrophy is less common. However, when it comes to isolated hypertrophy of the temporal muscle, very few unilateral cases have been reported, while only 5 cases of isolated bilateral temporal hypertrophy are available.</p><p>In order to accurately diagnose these rare cases, other possibilities such as tumoral masses, hematoma, myositis and intracranial pathologies should be excluded in the differential diagnosis. In cases of temporal muscle hypertrophy unrelated to bruxism, there may be adaptive hypertrophy due to pathologic conditions in the muscle<sup><xref rid="ref8" ref-type="bibr">8</xref>,<xref rid="ref17" ref-type="bibr">17</xref></sup>. Imaging modalities, especially MRI, are highly valuable in the diagnosis<sup><xref rid="ref17" ref-type="bibr">17</xref></sup>. BTxA injection is a treatment that has been proven to be both effective and safe<sup><xref rid="ref18" ref-type="bibr">18</xref></sup>. It has been shown to provide symptomatic relief in patients without the need for surgery. Although surgical methods can provide permanent reduction of muscle volume, they carry increased risks such as infection, bleeding and nerve damage<sup><xref rid="ref9" ref-type="bibr">9</xref></sup>. BTxA applications are a preferred low-risk alternative.</p><p>In the literature, BTxA doses administered to the temporal muscle are generally in the range of 20 Units each to both temporal muscle regions<sup><xref rid="ref8" ref-type="bibr">8</xref></sup>. In our case, 15 units were administered bilaterally in two sessions (60 Units in total) and clinical improvement was achieved. Subsequent to BTxA administration, the 4th week and 8th week controls are of paramount importance. It is recommended to repeat the treatment every 4 to 6 months for about 2-3 years in order to achieve a long-lasting effect<sup><xref rid="ref8" ref-type="bibr">8</xref></sup>. The onset of the effect after application occurs in an average of 6.7&#177;5 days, and the duration of the therapeutic effect obtained is reported to be 78.5&#177;28.4 days on average<sup><xref rid="ref19" ref-type="bibr">19</xref></sup>. In 5 other cases of bilateral temporal hypertrophy reported in the literature, significant clinical improvement was also reported with BTxA<sup><xref rid="ref3" ref-type="bibr">3</xref><xref rid="ref4" ref-type="bibr"/><xref rid="ref5" ref-type="bibr"/><xref rid="ref6" ref-type="bibr"/>-<xref rid="ref7" ref-type="bibr">7</xref></sup>.</p><p>IBTMH remains an rare clinical entity, with limited cases reported in the literature. This case contributes to the understanding and management of IBTMH by demonstrating the effectiveness of BTxA as a non-invasive therapeutic modality. Guided BTxA injections, based on clinical and MRI findings, provided effective symptom and cosmetic relief without complications. Further review of the literature on injection methods, along with continued case reports, is essential to establish clear clinical guidelines for the diagnosis and management of IBTMH.</p></sec></body><back><fn-group><fn fn-type="con"><p>
<bold>Authors&#8217; Contributions</bold>
</p><p>S.A. contributed to data collection and manuscript writing. S.A., &#214;.U., and B.G. were involved in study design, case management, and overall coordination, and also contributed to drafting the manuscript. All authors read and approved the final version of the manuscript.</p></fn><fn fn-type="supported-by"><p>
<bold>Funding</bold>
</p><p>No funding to declare.</p></fn><fn><p>
<bold>Consent for Publishing Photographs</bold>
</p><p>Written informed consent was obtained from the patient for publication of this article and accompanying images.</p></fn><fn fn-type="COI-statement"><p>
<bold>Conflict of Interest</bold>
</p><p>No potential conflict of interest relevant to this article was reported.</p></fn></fn-group><ref-list><title>References</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Legg</surname><given-names>JW</given-names></name></person-group><year>1880</year><article-title>Enlargement of the temporal and masseter muscles on both sides</article-title><source>Trans Pathol Soc Lond</source><volume>31</volume><fpage>361</fpage><lpage>6</lpage></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Basit</surname><given-names>H</given-names></name><name name-style="western"><surname>Tariq</surname><given-names>MA</given-names></name><name name-style="western"><surname>Siccardi</surname><given-names>MA</given-names></name></person-group><person-group person-group-type="editor"><name name-style="western"><surname>Abdelsattar</surname><given-names>M</given-names></name><name name-style="western"><surname>Ackley</surname><given-names>WB</given-names></name><name name-style="western"><surname>Adolphe</surname><given-names>TS</given-names></name><name name-style="western"><surname>Aeby</surname><given-names>TC</given-names></name><name name-style="western"><surname>Agadi</surname><given-names>S</given-names></name><name name-style="western"><surname>Agasthi</surname><given-names>P</given-names></name></person-group><year>2019</year><part-title>Anatomy, head and neck, mastication muscles</part-title><source>StatPearls</source><publisher-name>StatPearls Publishing</publisher-name><pub-id pub-id-type="pmid">31082071</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Da Silva</surname><given-names>K</given-names></name><name name-style="western"><surname>Mandel</surname><given-names>L</given-names></name></person-group><year>2006</year><article-title>Bilateral temporalis muscle hypertrophy: a case report</article-title><source>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</source><volume>102</volume><fpage>e1</fpage><lpage>3</lpage><comment><uri xlink:href="https://doi.org/10.1016/j.tripleo.2006.02.002">https://doi.org/10.1016/j.tripleo.2006.02.002</uri></comment><pub-id pub-id-type="doi">10.1016/j.tripleo.2006.02.002</pub-id><pub-id pub-id-type="pmid">16831662</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ali</surname><given-names>K</given-names></name><name name-style="western"><surname>Sittampalam</surname><given-names>G</given-names></name><name name-style="western"><surname>Malik</surname><given-names>MA</given-names></name></person-group><year>2010</year><article-title>Bilateral temporalis hypertrophy</article-title><source>Int J Oral Maxillofac Surg</source><volume>39</volume><fpage>305</fpage><lpage>7</lpage><comment><uri xlink:href="https://doi.org/10.1016/j.ijom.2009.09.005">https://doi.org/10.1016/j.ijom.2009.09.005</uri></comment><pub-id pub-id-type="doi">10.1016/j.ijom.2009.09.005</pub-id><pub-id pub-id-type="pmid">19836926</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rokadiya</surname><given-names>S</given-names></name><name name-style="western"><surname>Malden</surname><given-names>NJ</given-names></name></person-group><year>2006</year><article-title>Variable presentation of temporalis hypertrophy--a case report with literature review</article-title><source>Br Dent J</source><volume>201</volume><fpage>153</fpage><lpage>5</lpage><elocation-id>quiz 172</elocation-id><comment><uri xlink:href="https://doi.org/10.1038/sj.bdj.4813850">https://doi.org/10.1038/sj.bdj.4813850</uri></comment><pub-id pub-id-type="doi">10.1038/sj.bdj.4813850</pub-id><pub-id pub-id-type="pmid">16902544</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gomez</surname><given-names>JS</given-names></name><name name-style="western"><surname>Cuellar</surname><given-names>H</given-names></name></person-group><year>2020</year><article-title>Temporalis muscle hypertrophy: imaging and clinical implications</article-title><source>Open J Clin Med Case Rep</source><volume>6</volume><fpage>1679</fpage></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pasupathy</surname><given-names>S</given-names></name><name name-style="western"><surname>Yuvaraj</surname><given-names>V</given-names></name></person-group><year>2010</year><article-title>Peculiar presentation of bilateral temporalis muscle hypertrophy--report of a case and review of literature</article-title><source>Oral Maxillofac Surg</source><volume>14</volume><fpage>183</fpage><lpage>5</lpage><comment><uri xlink:href="https://doi.org/10.1007/s10006-009-0195-z">https://doi.org/10.1007/s10006-009-0195-z</uri></comment><pub-id pub-id-type="doi">10.1007/s10006-009-0195-z</pub-id><pub-id pub-id-type="pmid">20099005</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Graziano</surname><given-names>P</given-names></name><name name-style="western"><surname>Dell'Aversana Orabona</surname><given-names>G</given-names></name><name name-style="western"><surname>Astarita</surname><given-names>F</given-names></name><name name-style="western"><surname>Ponzo</surname><given-names>LM</given-names></name><name name-style="western"><surname>Nunziata</surname><given-names>R</given-names></name><name name-style="western"><surname>Salzano</surname><given-names>G</given-names></name><etal/></person-group><year>2016</year><article-title>Bilateral hypertrophy of masseteric and temporalis muscles, our fifteen patients and review of literature</article-title><source>Eur Rev Med Pharmacol Sci</source><volume>20</volume><fpage>7</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">26813447</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morselli</surname><given-names>PG</given-names></name></person-group><year>2000</year><article-title>Temporalis muscle hypertrophy: a new plastic surgery procedure</article-title><source>Plast Reconstr Surg</source><volume>106</volume><fpage>1156</fpage><lpage>61</lpage><comment><uri xlink:href="https://doi.org/10.1097/00006534-200010000-00028">https://doi.org/10.1097/00006534-200010000-00028</uri></comment><pub-id pub-id-type="doi">10.1097/00006534-200010000-00028</pub-id><pub-id pub-id-type="pmid">11039387</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>WK</given-names></name><name name-style="western"><surname>Bae</surname><given-names>JH</given-names></name><name name-style="western"><surname>Hu</surname><given-names>KS</given-names></name><name name-style="western"><surname>Kato</surname><given-names>T</given-names></name><name name-style="western"><surname>Kim</surname><given-names>ST</given-names></name></person-group><year>2017</year><article-title>Anatomical recommendations for safe botulinum toxin injection into temporalis muscle: a simplified reproducible approach</article-title><source>Surg Radiol Anat</source><volume>39</volume><fpage>263</fpage><lpage>9</lpage><comment><uri xlink:href="https://doi.org/10.1007/s00276-016-1739-1">https://doi.org/10.1007/s00276-016-1739-1</uri></comment><pub-id pub-id-type="doi">10.1007/s00276-016-1739-1</pub-id><pub-id pub-id-type="pmid">27631881</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Lierde</surname><given-names>S</given-names></name></person-group><year>1985</year><article-title>Chewer's cheeks: a case of bilateral temporal muscle swelling</article-title><source>Pediatr Emerg Care</source><volume>1</volume><fpage>136</fpage><lpage>7</lpage><comment><uri xlink:href="https://doi.org/10.1097/00006565-198509000-00006">https://doi.org/10.1097/00006565-198509000-00006</uri></comment><pub-id pub-id-type="doi">10.1097/00006565-198509000-00006</pub-id><pub-id pub-id-type="pmid">3842883</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yi</surname><given-names>KH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Hur</surname><given-names>HW</given-names></name><name name-style="western"><surname>Seo</surname><given-names>KK</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HJ</given-names></name></person-group><year>2022</year><article-title>Guidelines for botulinum neurotoxin injection for facial contouring</article-title><source>Plast Reconstr Surg</source><volume>150</volume><fpage>562e</fpage><lpage>571e</lpage><comment><uri xlink:href="https://doi.org/10.1097/prs.0000000000009444">https://doi.org/10.1097/prs.0000000000009444</uri></comment><pub-id pub-id-type="doi">10.1097/PRS.0000000000009444</pub-id><pub-id pub-id-type="pmid">35759641</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prado</surname><given-names>A</given-names></name><name name-style="western"><surname>Fuentes</surname><given-names>P</given-names></name><name name-style="western"><surname>Guerra</surname><given-names>C</given-names></name><name name-style="western"><surname>Leniz</surname><given-names>P</given-names></name><name name-style="western"><surname>Wisnia</surname><given-names>P</given-names></name></person-group><year>2007</year><article-title>Pseudoaneurysm of the frontal branch of the superficial temporal artery: an unusual complication after the injection of botox</article-title><source>Plast Reconstr Surg</source><volume>119</volume><fpage>2334</fpage><lpage>5</lpage><comment><uri xlink:href="https://doi.org/10.1097/01.prs.0000261095.07321.09">https://doi.org/10.1097/01.prs.0000261095.07321.09</uri></comment><pub-id pub-id-type="doi">10.1097/01.prs.0000261095.07321.09</pub-id><pub-id pub-id-type="pmid">17519763</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guyuron</surname><given-names>B</given-names></name><name name-style="western"><surname>Rose</surname><given-names>K</given-names></name><name name-style="western"><surname>Kriegler</surname><given-names>JS</given-names></name><name name-style="western"><surname>Tucker</surname><given-names>T</given-names></name></person-group><year>2004</year><article-title>Hourglass deformity after botulinum toxin type A injection</article-title><source>Headache</source><volume>44</volume><fpage>262</fpage><lpage>4</lpage><comment><uri xlink:href="https://doi.org/10.1111/j.1526-4610.2004.04058.x">https://doi.org/10.1111/j.1526-4610.2004.04058.x</uri></comment><pub-id pub-id-type="doi">10.1111/j.1526-4610.2004.04058.x</pub-id><pub-id pub-id-type="pmid">15012666</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skaf</surname><given-names>GS</given-names></name><name name-style="western"><surname>Domloj</surname><given-names>NT</given-names></name><name name-style="western"><surname>Salameh</surname><given-names>JA</given-names></name><name name-style="western"><surname>Atiyeh</surname><given-names>B</given-names></name></person-group><year>2012</year><article-title>Pseudoaneurysm of the superficial temporal artery: a complication of botulinum toxin injection</article-title><source>Aesthetic Plast Surg</source><volume>36</volume><fpage>982</fpage><lpage>5</lpage><comment><uri xlink:href="https://doi.org/10.1007/s00266-012-9881-6">https://doi.org/10.1007/s00266-012-9881-6</uri></comment><pub-id pub-id-type="doi">10.1007/s00266-012-9881-6</pub-id><pub-id pub-id-type="pmid">22527583</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Lee</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Lee</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Lee</surname><given-names>KW</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Hu</surname><given-names>KS</given-names></name></person-group><year>2016</year><article-title>Effective botulinum toxin injection guide for treatment of temporal headache</article-title><source>Toxins (Basel)</source><volume>8</volume><fpage>265</fpage><comment><uri xlink:href="https://doi.org/10.3390/toxins8090265">https://doi.org/10.3390/toxins8090265</uri></comment><pub-id pub-id-type="doi">10.3390/toxins8090265</pub-id><pub-id pub-id-type="pmid">27618099</pub-id><pub-id pub-id-type="pmcid">PMC5037491</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lowry</surname><given-names>TR</given-names></name><name name-style="western"><surname>Helling</surname><given-names>E</given-names></name></person-group><year>2003</year><article-title>Unilateral temporal muscle hypertrophy: a rare clinical entity</article-title><source>Ear Nose Throat J</source><volume>82</volume><fpage>198</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1177/014556130308200313</pub-id><pub-id pub-id-type="pmid">12696240</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Isaac</surname><given-names>AM</given-names></name></person-group><year>2000</year><article-title>Unilateral temporalis muscle hypertrophy managed with botulinum toxin type A</article-title><source>Br J Oral Maxillofac Surg</source><volume>38</volume><fpage>571</fpage><lpage>2</lpage><comment><uri xlink:href="https://doi.org/10.1054/bjom.2000.0298">https://doi.org/10.1054/bjom.2000.0298</uri></comment><pub-id pub-id-type="doi">10.1054/bjom.2000.0298</pub-id><pub-id pub-id-type="pmid">11010798</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ledda</surname><given-names>C</given-names></name><name name-style="western"><surname>Artusi</surname><given-names>CA</given-names></name><name name-style="western"><surname>Tribolo</surname><given-names>A</given-names></name><name name-style="western"><surname>Rinaldi</surname><given-names>D</given-names></name><name name-style="western"><surname>Imbalzano</surname><given-names>G</given-names></name><name name-style="western"><surname>Lopiano</surname><given-names>L</given-names></name><etal/></person-group><year>2022</year><article-title>Time to onset and duration of botulinum toxin efficacy in movement disorders</article-title><source>J Neurol</source><volume>269</volume><fpage>3706</fpage><lpage>12</lpage><comment><uri xlink:href="https://doi.org/10.1007/s00415-022-10995-2">https://doi.org/10.1007/s00415-022-10995-2</uri></comment><pub-id pub-id-type="doi">10.1007/s00415-022-10995-2</pub-id><pub-id pub-id-type="pmid">35113259</pub-id><pub-id pub-id-type="pmcid">PMC9217780</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="F1" orientation="portrait"><label>Fig. 1</label><caption><p>A. Extraoral facial views demonstrating swelling in the temporal region. B, C. Lateral view.</p></caption><graphic position="float" orientation="portrait" xlink:href="jkaoms-51-4-254-f1.jpg"/></fig><fig position="float" id="F2" orientation="portrait"><label>Fig. 2</label><caption><p>Initial magnetic resonance imaging scans showing hypertrophy of the temporalis muscle. To visualize the temporal muscle in greater detail, muscle thickness was measured on an axial T2-weighted image using the fast relaxation fast spin echo sequence with Array Spatial Sensitivity Encoding Technique (ASSET). The maximum mediolateral thickness of the muscle in the axial section was measured as &#8220;1.66 cm&#8221; on average. The green arrows indicate the width of the temporal muscle.</p></caption><graphic position="float" orientation="portrait" xlink:href="jkaoms-51-4-254-f2.jpg"/></fig><fig position="float" id="F3" orientation="portrait"><label>Fig. 3</label><caption><p>Clinical stage of botulinum toxin type A injection into the temporalis muscle. (A: anterior, S: superior, P: posterior, C: canthus, T: tragus, Am: anterior-middle, Mu: mid-upper, Pm: posterior-middle)</p></caption><graphic position="float" orientation="portrait" xlink:href="jkaoms-51-4-254-f3.jpg"/></fig><fig position="float" id="F4" orientation="portrait"><label>Fig. 4</label><caption><p>A. Post-treatment extraoral facial views showing regression of swelling. B, C. Lateral view 2 months after injection. D. Facial view. E, F. Lateral view 4 months after injection.</p></caption><graphic position="float" orientation="portrait" xlink:href="jkaoms-51-4-254-f4.jpg"/></fig><fig position="float" id="F5" orientation="portrait"><label>Fig. 5</label><caption><p>Postoperative imaging magnetic resonance imaging demonstrating reduction in muscle bulk. The green arrows show the temporal muscle.</p></caption><graphic position="float" orientation="portrait" xlink:href="jkaoms-51-4-254-f5.jpg"/></fig><fig position="float" id="F6" orientation="portrait"><label>Fig. 6</label><caption><p>Flowchart of botulinum toxin type A (BtxA) injection protocol.</p></caption><graphic position="float" orientation="portrait" xlink:href="jkaoms-51-4-254-f6.jpg"/></fig><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>Summary of reported cases of bilateral isolated temporalis muscle hypertrophy, including demographic data, clinical presentation, imaging modalities, and treatments</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="center" style="background-color:#eceded;" rowspan="1" colspan="1">Case report</th><th valign="middle" align="center" style="background-color:#eceded;" rowspan="1" colspan="1">Age (yr)/sex</th><th valign="middle" align="center" style="background-color:#eceded;" rowspan="1" colspan="1">Country</th><th valign="middle" align="center" style="background-color:#eceded;" rowspan="1" colspan="1">Symptom</th><th valign="middle" align="center" style="background-color:#eceded;" rowspan="1" colspan="1">Imaging method</th><th valign="middle" align="center" style="background-color:#eceded;" rowspan="1" colspan="1">Treatment</th></tr></thead><tbody><tr><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="1" colspan="1">Da Silva and Mandel<sup><xref rid="ref3" ref-type="bibr">3</xref></sup> (2006)</td><td valign="top" align="center" rowspan="1" colspan="1">44/F</td><td valign="top" align="center" rowspan="1" colspan="1">USA</td><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="1" colspan="1">Swelling, tenderness, pain</td><td valign="top" align="left" rowspan="1" colspan="1">NR</td><td valign="top" align="left" rowspan="1" colspan="1">NR</td></tr><tr><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="1" colspan="1">Rokadiya and Malden<sup><xref rid="ref5" ref-type="bibr">5</xref></sup> (2006)</td><td valign="top" align="center" rowspan="1" colspan="1">33/F</td><td valign="top" align="center" rowspan="1" colspan="1">UK</td><td valign="top" align="left" rowspan="1" colspan="1">Swelling, pain</td><td valign="top" align="left" rowspan="1" colspan="1">USG</td><td valign="top" align="left" rowspan="1" colspan="1">NR</td></tr><tr><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="1" colspan="1">Ali et al.<sup><xref rid="ref4" ref-type="bibr">4</xref></sup> (2010)</td><td valign="top" align="center" rowspan="1" colspan="1">38/F</td><td valign="top" align="center" rowspan="1" colspan="1">UK</td><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="1" colspan="1">Swelling, clenching, headache</td><td valign="top" align="left" rowspan="1" colspan="1">MRI, OPG</td><td valign="top" align="left" rowspan="1" colspan="1">BTxA</td></tr><tr><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="1" colspan="1">Gomez and Cuellar<sup><xref rid="ref6" ref-type="bibr">6</xref></sup> (2020)</td><td valign="top" align="center" rowspan="1" colspan="1">56/M</td><td valign="top" align="center" rowspan="1" colspan="1">USA</td><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="1" colspan="1">No symptom (incidental)</td><td valign="top" align="left" rowspan="1" colspan="1">MRI</td><td valign="top" align="left" rowspan="1" colspan="1">NR</td></tr><tr><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="1" colspan="1">Pasupathy and Yuvaraj<sup><xref rid="ref7" ref-type="bibr">7</xref></sup> (2010)</td><td valign="top" align="center" rowspan="1" colspan="1">32/M</td><td valign="top" align="center" rowspan="1" colspan="1">India</td><td valign="top" align="left" rowspan="1" colspan="1">Painless swelling</td><td valign="top" align="left" rowspan="1" colspan="1">Doppler USG, CT</td><td valign="top" align="left" rowspan="1" colspan="1">NR</td></tr></tbody></table><table-wrap-foot><fn id="t1fn1"><p>(F: female, M: male, NR: not reported, USG: ultrasonography, OPG: orthopantomogram, MRI: magnetic resonance imaging, CT: computed tomography, BTxA: botulinum toxin type A)</p></fn></table-wrap-foot></table-wrap></floats-group></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>